This study is a randomized, double blinded study that will evaluate the safety and efficacy of the subcutaneous P2Y12 inhibitor selatogrel self-administered for the prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction.